CAMBRIDGE, Mass. and BEIJING, China, Feb. 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused
on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today
announced that the company will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY. The
presentation is scheduled for 10:00 a.m. EST on Friday, March 1st, 2019.
A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the
event.
About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology
cancer therapeutics. With a team of over 1,700 employees in China, the United States, Australia and Switzerland, BeiGene is
advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to
create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets
ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA®
(azacitidine) in China under a license from Celgene Corporation.i
Investor Contact
Craig West
+1 857-302-5189
ir@beigene.com
Media Contact
Liza Heapes
+1 857-302-5663
media@beigene.com
_____________________________
i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.
